

*East Midlands Cancer Alliance Collaboration:
Optimising the Specialist Skin Cancer MDT pathway.*

Summary of Collaborative Working Project	The collaborative working programme with Regeneron and East Midlands Cancer Alliance aims to co-develop and implement resources, standardised templates and processes to disseminate cross the region to improve the efficiency of the skin cancer MDT's across East Midlands Cancer Alliance. The programme will also support implementation of the standardised processes in 1 hospital across the region with their prior agreement.
The organisations involved	East Midlands Cancer Alliance ("EMCA") Leicestershire County Hall, Glenfield, Leicester LE3 8HD. Regeneron The Charter Building, Vine Street, Uxbridge, Middlesex, UB8 1JG
Objectives of the Project	Co-develop East Midlands Cancer Alliance processes and templates to support standardisation of MDTs across the East Midlands region. Delivers a practical implementation and dissemination plan, pilots adoption in one hospital to generate shared learning, and establishes a monitoring and evaluation framework that can be scaled across hospitals in the region.
Expected outcomes	<u>Patients</u> - Reduction in delays, leading to more efficient communication to patients from the MDT, and therefore an opportunity to support patients along the process. - Earlier communication of a treatment plan, due to a more efficient MDT process. - Improved patient outcomes <u>East Midlands Cancer Alliance and Hospitals where optimisation is delivered</u> - Potential improvement in use of limited staff resources when supporting the MDT process. - Improvements in staff satisfaction. - Enhance quality of service. - Improve cancer waiting times performance. - Shared learning across the Cancer Alliance. <u>Regeneron</u> - Building a collaborative working relationship with the NHS - Showing evidence of expertise and offering to support optimal care for patients. - May provide improved access to treatments in line with NICE guidance which may or may not include Regeneron medicines
Time Frame	August 2026 – December 2026